Urodynamix Technologies Ltd. announced that it has obtained a CE Mark for the UroNIRS 2000 Bladder Monitor System and will officially launch the product in Europe with its distribution partner Medical Measurement Systems B.V. (MMS) at the Annual EAU Conference in Stockholm Sweden. The granting of the CE Mark will allow Urodynamix to expand distribution of its UroNIRS products into the urology office and outpatient markets in Europe where millions of men suffer from the symptoms of benign prostatic hyperplasia (BPH) and require effective diagnosis prior to treatment. Urodynamix expects to commence commercial shipments of UroNIRS 2000 to Europe in the first quarter of 2009. “The receipt of the CE Mark sets the stage for our rollout of the uroNIRS technology in Europe. We are very pleased to have achieved this major milestone.” said Barry Allen, President and CEO of Urodynamix. “The UroNIRS 2000 is a key part of our expansion from the acute care market into the larger office based urology market and Europe is a major market to have access to. The UroNIRS 2000 is a user friendly and cost effective device for the urology office market where we believe the noninvasive fast diagnostic procedure will have incredible value." “MMS is a market leader in urodynamics and we are looking forward to introducing and promoting this exciting new technology,” said Arjen J. de Weerd, President of MMS. “By being able to provide Urodynamix’s UroNIRS technology on a standalone basis we will continue to provide the latest advances in noninvasive diagnostic technology to our global customer base.” The UroNIRS 2000 is based on a wireless tablet PC with Urodynamix’s proprietary sensor configuration. It is compact, portable and specifically designed for ease of use in the urologist’s office setting. The UroNIRS 2000 utilizes a noninvasive procedure to confirm the presence of bladder outlet obstruction in men by identifying patients that have healthy bladder function yet suffer from weak urinary stream, hesitancy, urinary retention and related symptoms. UroNIRS 2000 is safer, faster, less expensive and more comfortable than conventional catheterbased diagnostics used to identify the same condition. Clinical studies have shown that the UroNIRS 2000 device has an 86% success rate for accurately identifying obstructed male patients, most of whom are good surgical candidates.